Clearbridge Investments LLC Buys New Position in TG Therapeutics, Inc. (NASDAQ:TGTX)

Clearbridge Investments LLC acquired a new position in TG Therapeutics, Inc. (NASDAQ:TGTX - Free Report) during the 4th quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 1,835,127 shares of the biopharmaceutical company's stock, valued at approximately $55,237,000. Clearbridge Investments LLC owned about 1.18% of TG Therapeutics at the end of the most recent quarter.

Other institutional investors and hedge funds have also bought and sold shares of the company. Blue Trust Inc. lifted its holdings in shares of TG Therapeutics by 24.5% during the 4th quarter. Blue Trust Inc. now owns 1,887 shares of the biopharmaceutical company's stock worth $57,000 after acquiring an additional 371 shares during the last quarter. Smartleaf Asset Management LLC boosted its holdings in shares of TG Therapeutics by 512.5% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,905 shares of the biopharmaceutical company's stock worth $60,000 after purchasing an additional 1,594 shares in the last quarter. Jones Financial Companies Lllp increased its position in shares of TG Therapeutics by 460.7% during the 4th quarter. Jones Financial Companies Lllp now owns 2,114 shares of the biopharmaceutical company's stock valued at $64,000 after purchasing an additional 1,737 shares during the last quarter. Synergy Asset Management LLC bought a new stake in TG Therapeutics in the 4th quarter worth approximately $75,000. Finally, GAMMA Investing LLC grew its position in TG Therapeutics by 562.4% during the fourth quarter. GAMMA Investing LLC now owns 2,557 shares of the biopharmaceutical company's stock valued at $77,000 after acquiring an additional 2,171 shares during the last quarter. 58.58% of the stock is owned by hedge funds and other institutional investors.

Remove Ads

Analyst Upgrades and Downgrades

Several equities analysts recently issued reports on the company. StockNews.com upgraded TG Therapeutics from a "sell" rating to a "hold" rating in a research report on Tuesday, March 4th. HC Wainwright restated a "buy" rating and issued a $55.00 target price on shares of TG Therapeutics in a report on Tuesday, March 4th. Two analysts have rated the stock with a hold rating and five have given a buy rating to the company's stock. According to data from MarketBeat, TG Therapeutics has an average rating of "Moderate Buy" and an average price target of $40.67.

Insider Activity at TG Therapeutics

In other TG Therapeutics news, CFO Sean A. Power sold 11,337 shares of the company's stock in a transaction dated Friday, January 3rd. The shares were sold at an average price of $30.29, for a total transaction of $343,397.73. Following the transaction, the chief financial officer now owns 670,632 shares in the company, valued at approximately $20,313,443.28. This represents a 1.66 % decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 10.50% of the stock is currently owned by insiders.

TG Therapeutics Trading Down 1.2 %

Shares of TG Therapeutics stock traded down $0.48 during midday trading on Thursday, reaching $39.34. 2,458,603 shares of the company's stock traded hands, compared to its average volume of 3,075,549. The stock has a 50 day moving average of $34.94 and a 200-day moving average of $30.67. TG Therapeutics, Inc. has a 12 month low of $12.93 and a 12 month high of $43.32. The company has a market cap of $6.18 billion, a PE ratio of -393.36 and a beta of 2.13. The company has a debt-to-equity ratio of 1.27, a quick ratio of 3.91 and a current ratio of 4.59.

TG Therapeutics (NASDAQ:TGTX - Get Free Report) last posted its quarterly earnings data on Monday, March 3rd. The biopharmaceutical company reported $0.15 earnings per share for the quarter, beating the consensus estimate of $0.08 by $0.07. TG Therapeutics had a negative return on equity of 8.32% and a negative net margin of 5.42%. The business had revenue of $108.19 million for the quarter, compared to analysts' expectations of $100.67 million. As a group, equities analysts expect that TG Therapeutics, Inc. will post 0.08 EPS for the current fiscal year.

About TG Therapeutics

TG Therapeutics, Inc, a commercial stage biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel treatments for B-cell mediated diseases in the United States and internationally. It provides BRIUMVI, an anti-CD20 monoclonal antibody for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease in adults.